Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042109 (urticaria)
 6,569 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Ketotifen is an orally active prophylactic agent for the management of bronchial asthma and allergic disorders. Accumulated evidence indicates that after 6 to 12 weeks of administration, ketotifen significantly reduces respiratory symptoms and the need for concomitant antiasthmatic drugs in about 70% and 50%, respectively, of patients with mild to moderate bronchial asthma. However, absolute improvement in lung function is generally slight. Ketotifen also has pronounced antihistaminic and antianaphylactic properties which result in moderate to marked symptom improvement in the majority of patients with atopic dermatitis, seasonal or perennial rhinitis, allergic conjunctivitis, chronic or acute urticaria or food allergy. Comparative trials with established agents--notably sodium cromoglycate (cromolyn sodium) in asthma and histamine H1-antagonists in allergic disorders--indicate that ketotifen has comparable clinical utility. Unlike inhaled sodium cromoglycate, ketotifen ameliorates the symptoms of asthma, rhinitis and dermatitis when present together in atopic patients. Patient acceptance of ketotifen is good, although sedation can be troublesome in older children and adults for the initial 2 weeks of treatment. Weight gain is another notable effect in a small percentage of patients. Thus, ketotifen appears to be a useful agent for the management of allergic disorders and bronchial asthma, particularly in patients for whom oral therapy is preferred. Although a lengthy run-in period is needed in the treatment of asthma, in those patients who respond, continued reduction in the frequency and severity of symptoms and in the use of additional antiasthmatic drugs can be anticipated.
 ...
PMID:Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. 222 22

The capacity for ketotifen to prevent mast-cell degranulation in vivo was studied in patients with physical urticarias. Patients were exposed to the appropriate stimulus to elicit their physical urticaria before and during ketotifen therapy. Histamine concentrations in plasma samples, obtained before and serially after the physical provocation, were determined by radioenzymatic thin-layer chromatography. Ketotifen therapy was associated with marked reductions in plasma histamine levels after stimulation and in clinical evidence of urticaria in each patient. A direct correlation of ketotifen therapy and a reduction in histamine release was confirmed in a patient with a cold-induced urticaria who was studied again after discontinuation and again after reinstitution of therapy. Although the mechanism of action is unknown, this report shows that ketotifen is capable of inhibiting cutaneous mast-cell degranulation and its accompanying symptoms. These findings suggest important therapeutic alternatives for patients with mast-cell-mediated diseases.
 ...
PMID:Prevention of mast-cell degranulation by ketotifen in patients with physical urticarias. 242 Feb 46

Ketotifen, an inhibitor of the mastocytes degranulation is used in the treatment of allergic asthma. The use of this drug in chronic urticaria is proposed because histamine play a major role in the production of the lesions. In this study, 36 patients with chronic urticaria of various aetiology are treated with ketotifen (2 mg/d). 12 patients were healed, 11 good results and 12 failure were obtained. The best results are obtained in cold urticaria and in food related urticaria. This result were compared with data concerning the treatment of chronic urticaria.
 ...
PMID:[Treatment of chronic urticaria with ketotifen]. 289 35

The cow-milk weaning sometimes comes with urticaria or others allergic signs, in relation with the anti cow-milk IgE presence, which rate was studied in 30 children at the time of the accident, after the putting back to the breast-feeding or a hydrolyzed proteins milk and after reintroduction of the cow-milk. They disappear in three cases out of four, shortly after the cow-milk suppression. They reappear in one case out of three from the reintroduction. Carried on CGDS or Ketotifen , the cow-milk tolerance was quickly obtained even in the children who conserved anti-cow milk IgE, and after the treatment stop. A spontaneous tolerance after the initial accident is possible. The characteristics of the anti-cow milk IgE response in the breast-fed new-born child are examined.
 ...
PMID:[Development of anti-cow's milk IgE in weaning allergy]. 339 Feb 97

Ketotifen, benzocycloheptathiophene, (Zaditen) an orally active, anti-allergic and anti-asthmatic drug in a dose of 1 mg twice daily was given from 2 to 20 months in 20 selected patients with food allergy (FA) or food intolerance (FI). Sixteen children and four adults of which ten had atopic dermatitis (AD), six urticaria or/and angiooedema (two of which with oropharynx pruritus, oedema of the lips and anaphylactic shock), two asthma, and two gastrointestinal disorders. Food allergy was proved by clinical history, exclusion diet positive challenge test, skin prick tests (SPT) total IgE (PRIST) and specific IgE (RAST). Gastrointestinal permeability was measured in 5 out of 20 patients using mannitol and lactulose as probe molecules on three occasions: (1) by ingestion of the markers alone, (2) with concomitant ingestion of the offending food(s), and (3) with previous administration of ketotifen (2 mg) six hours before ingestion of markers and offending food. In all five individuals, food ingestion resulted in a significant rise of lactulose: mannitol urinary ratio and previous administration of ketotifen resulted in a normalization of the mannitol:lactulose urinary ratio. Patients with urticaria and/or angiooedema, gastrointestinal symptoms, asthma, and oropharynx pruritus with oedema of the lips were completely protected. In patients with AD, 70% were greatly improved or improved but 30% remained the same. It is our impression that ketotifen offers a new therapeutic dimension and therapy in FA.
 ...
PMID:Ketotifen in prevention and therapy of food allergy. 368 73

Forty patients with urticaria, 13 with cholinergic urticaria, 22 with urticaria factitia, and 5 with both types of urticaria, were treated with ketotifen or placebo in a double-blind crossover study. Five patients dropped out, one because of excessive weight gain. In 23 of 24 patients with urticaria factitia, ketotifen caused a marked reduction of wealing and pruritus. In contrast, only 62% of the patients with cholinergic urticaria noticed a reduction of wealing, and 69% had reduced itching. Ketotifen caused few side effects, the most frequent one being mild tiredness in 9% of the patients. The beneficial effect of ketotifen in urticaria factitia and cholinergic urticaria may be due to its ability to reduce the liberation and the effectiveness of mast cell mediators.
 ...
PMID:[Effect of ketotifen in urticaria factitia and urticaria cholinergica in a crossover double-blind trial]. 390 13

Ketotifen, a benzocycloheptathiophene, possesses asthma-prophylactic and antiallergic activities in a number of in vitro and in vivo systems: prevention of cutaneous and lung anaphylaxis in the rat and guinea pig; inhibition of dermal and bronchial antigen challenges in man; inhibition of mediator release from rat mast cells, human basophils, human neutrophils, and human and guinea pig chopped lung; reduction of human neutrophil activation induced by PAF-acether; functional antagonism of mediator effects in the guinea pig; blockade of H1-receptors and prevention and reversal of beta-adrenergic tachyphylaxis in the rat. These properties make ketotifen suitable for the long-term prophylaxis of bronchial asthma and for the prevention and treatment of other allergic disorders, such as allergic rhinitis and conjunctivitis, food allergy, and urticaria. Oral ketotifen (1 mg twice daily) is particularly convenient in the management of the multiple allergies often encountered in patients with atopy.
 ...
PMID:Immunologic and therapeutic aspects of ketotifen. 401 61

Ketotifen administered prior to aspirin offered protection against bronchoconstriction in 13 of 14 patients with aspirin-sensitive asthma. In four other subjects, suffering from urticaria/angioedema following ingestion of aspirin-like drugs, pretreatment with ketotifen resulted in total prevention of the adverse reactions. These results support the suggestion of a common pathogenetic mechanism operating in two distinct clinical patterns of idiosyncrasy to aspirin and other cyclo-oxygenase inhibitors. They also indicate that ketotifen might find application in treatment of adverse reactions to aspirin.
 ...
PMID:Inhibition by ketotifen of idiosyncratic reactions to aspirin. 610 27

A new drug with inhibitory properties on the Mast Cell degranulation, Ketotifen, was administered in 87 patients suffering from idiopathic urticaria a frigore (iUF). The first group (A), with 52 patients effectuated prophylactic management for 4 months with Ketotifen (K) (2 mg/day) and Clemastine (C) (2 mg/day) according to the double blind crossover method. Both the drugs were administrated in stages of 2 months each. The second group (B), with 35 patients (having previously failed a prophylactic attempt with Cyproheptadine) received only K, for two months. The results of group. A were favourable (clinical improvements over 50%) in 86.6% of the patients treated with K and in 50% of the patients treated with C. The mention is made that 36.6% from favourable results obtained with C in the second stage, appeared as a continuation of the improvements determined by K in the first stage. The lowering of the skin response to Cold Test (CT) was obtained in 55.8% of the patients treated with K and only in 7.6% of them who received C. Group B obtained favourable clinical results in 62% cases and the diminution of CT in 42% cases. Finally a few lesser known clinical and aetiopathogenic aspects of iUF resulting from the analysis of the patients investigated are presented.
 ...
PMID:Clinical and therapeutical aspects of cold urticaria (urticaria a frigore). 620 72

26 male and female patients, suffering chronic idiopathic urticaria and angioneurotic edema, are treated with a new synthase molecule, Ketotifen, which offers a polivalent action. Among the patients there was a great majority of females (61,5%) their mean age being 35 years. The mean duration of this urticaria was 57,3 months, being even longer in male patients. In eleven of these cases there was a previous history of atopy in their families, and sixteen patients had some episodes of atopy in the past. All the patients were treated with ketotifen, in 1 mg. tablets, usually administered before meals, with partial doses no higher than 1 mg. 3 times a day, and a total dosage ranging from 28 to 180 mg. With this dosage we attained satisfactory results in 80,8% of the cases, with complete curation in 16 patients and a remarkable improvement of symptoms in 5 patients. In only two of the cases there was no response to the treatment. Tolerance to this drug was excellent in 88,6% of the patients. For all these reasons we consider ketotifen as an excellent therapeutic agent in Chronic Idiopathic Urticaria and Angioneurotic Edema, especially in those cases in which traditional therapies have failed. We also think that ketotifen, in association with other drugs, for example, terbutaline ( SAIHAN ) may solve, at least in some patients, the therapeutical problem that these conditions present. Furthermore, the nearly complete absence of important secondary effects, as observed in our study, makes it the treatment of choice in patients with gastric intolerance to drugs, or in those patients that, owing to their occupational activities, might be exposed to a high risk of laboral accidents.
 ...
PMID:[Ketotifen in the treatment of chronic urticaria and angioneurotic edema]. 673 Dec 2


1 2 Next >>